Hua Medicine Turns to 2025 Profit; Shares Soar 10%

MT Newswires Live

Mar 27

Hua Medicine (Shanghai) (HKG:2552) recorded a profit of 1.11 billion yuan in 2025, compared with a loss of 250.1 million yuan a year prior, according to a Thursday Hong Kong bourse filing.

Shares of the Chinese drugmaker were up over 10% in Friday afternoon trading.

Earnings per share stood at 1.10 yuan for the period, compared with a loss per share of 0.25 yuan in the previous fiscal year.

The pharmaceutical company's revenue surged to 492.9 million yuan from 255.9 million yuan previously, generated mainly from the sale of core product HuaTangNing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2622846835"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622846835\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622846835?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 15:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622846835","market":"sh","top_or_hot":-1,"title":"Hua Medicine Turns to 2025 Profit; Shares Soar 10%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/HUMDF\">Hua Medicine</a> (Shanghai) (HKG:2552) recorded a profit of 1.11 billion yuan in 2025, compared with a loss of 250.1 million yuan a year prior, according to a Thursday Hong Kong bourse filing.</p><p>Shares of the Chinese drugmaker were up over 10% in Friday afternoon trading.</p><p>Earnings per share stood at 1.10 yuan for the period, compared with a loss per share of 0.25 yuan in the previous fiscal year.</p><p>The pharmaceutical company's revenue surged to 492.9 million yuan from 255.9 million yuan previously, generated mainly from the sale of core product HuaTangNing.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hua Medicine Turns to 2025 Profit; Shares Soar 10%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHua Medicine Turns to 2025 Profit; Shares Soar 10%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-27 15:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/HUMDF\">Hua Medicine</a> (Shanghai) (HKG:2552) recorded a profit of 1.11 billion yuan in 2025, compared with a loss of 250.1 million yuan a year prior, according to a Thursday Hong Kong bourse filing.</p><p>Shares of the Chinese drugmaker were up over 10% in Friday afternoon trading.</p><p>Earnings per share stood at 1.10 yuan for the period, compared with a loss per share of 0.25 yuan in the previous fiscal year.</p><p>The pharmaceutical company's revenue surged to 492.9 million yuan from 255.9 million yuan previously, generated mainly from the sale of core product HuaTangNing.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2622846835","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622846835","pubTimestamp":1774598343,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hua Medicine   recorded a profit of 1.11 billion yuan in 2025, compared with a loss of 250.1 million yuan a year prior, according to a Thursday Hong Kong bourse filing.Shares of the Chinese drugmaker were up over 10% in Friday afternoon trading.Earnings per share stood at 1.10 yuan for the period, compared with a loss per share of 0.25 yuan in the previous fiscal year.The pharmaceutical company's revenue surged to 492.9 million yuan from 255.9 million yuan previously, generated mainly from the sale of core product HuaTangNing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK1191":"制药","HUMDF":"Hua Medicine","BK1574":"生物医药B类股","02552":"华领医药-B"},"translate_title":"华领医药转2025年盈利；股价飙升10%","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HUMDF":1.5,"02552":1},"content_text":"Hua Medicine (Shanghai) (HKG:2552) recorded a profit of 1.11 billion yuan in 2025, compared with a loss of 250.1 million yuan a year prior, according to a Thursday Hong Kong bourse filing.Shares of the Chinese drugmaker were up over 10% in Friday afternoon trading.Earnings per share stood at 1.10 yuan for the period, compared with a loss per share of 0.25 yuan in the previous fiscal year.The pharmaceutical company's revenue surged to 492.9 million yuan from 255.9 million yuan previously, generated mainly from the sale of core product HuaTangNing.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}